PROCEPT BioRobotics Co. (NASDAQ:PRCT) Given Average Rating of "Moderate Buy" by Brokerages

PROCEPT BioRobotics Co. (NASDAQ:PRCT - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $94.29.

A number of research analysts have weighed in on PRCT shares. Wells Fargo & Company reaffirmed an "overweight" rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Truist Financial restated a "buy" rating and set a $90.00 target price (down previously from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. Finally, Morgan Stanley decreased their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th.

Insider Transactions at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the completion of the transaction, the chief financial officer now directly owns 107,991 shares of the company's stock, valued at $6,161,966.46. This trade represents a 0.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Reza Zadno sold 5,475 shares of the company's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the completion of the sale, the chief executive officer now owns 173,070 shares in the company, valued at approximately $9,875,374.20. This trade represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,455 shares of company stock valued at $368,322. 17.40% of the stock is currently owned by insiders.

Remove Ads

Institutional Trading of PROCEPT BioRobotics

Hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC grew its position in shares of PROCEPT BioRobotics by 11.9% in the 4th quarter. FMR LLC now owns 8,159,208 shares of the company's stock worth $656,979,000 after acquiring an additional 866,328 shares in the last quarter. Vanguard Group Inc. boosted its holdings in PROCEPT BioRobotics by 6.1% in the fourth quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock worth $413,907,000 after purchasing an additional 297,075 shares during the period. Alliancebernstein L.P. increased its stake in PROCEPT BioRobotics by 14.2% during the fourth quarter. Alliancebernstein L.P. now owns 1,752,478 shares of the company's stock valued at $141,110,000 after purchasing an additional 218,148 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of PROCEPT BioRobotics by 38.8% during the fourth quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock worth $120,051,000 after purchasing an additional 416,819 shares during the period. Finally, State Street Corp lifted its position in shares of PROCEPT BioRobotics by 5.9% in the 3rd quarter. State Street Corp now owns 1,179,514 shares of the company's stock worth $94,503,000 after buying an additional 66,175 shares during the last quarter. 89.46% of the stock is owned by institutional investors.

PROCEPT BioRobotics Trading Up 0.4 %

PROCEPT BioRobotics stock traded up $0.23 during trading on Wednesday, reaching $58.10. The company had a trading volume of 666,081 shares, compared to its average volume of 725,667. PROCEPT BioRobotics has a 12-month low of $45.56 and a 12-month high of $103.81. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The stock's 50 day moving average price is $67.15 and its two-hundred day moving average price is $78.32. The firm has a market capitalization of $3.18 billion, a price-to-earnings ratio of -29.79 and a beta of 1.05.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The firm had revenue of $68.24 million for the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. As a group, equities analysts expect that PROCEPT BioRobotics will post -1.75 earnings per share for the current fiscal year.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).